In this QCast episode, co-hosts Jullia and Tom explore observational studies and why they remain such an important part of evidence generation in drug development. They clarify what observational studies mean in day-to-day research work: non-interventional studies where treatment decisions happen through usual care, while researchers analyse exposures, outcomes, and patient characteristics using data collected outside a controlled trial setting. The conversation focuses on where teams are most exposed when working this way, including unclear study questions, uneven data quality, baseline differences between treatment groups, and the knock-on effect those issues can have on how confidently results can be interpreted.
They also discuss what observational studies are really there to do. They can help answer questions that randomised trials do not always address fully, especially around broader patient populations, longer-term outcomes, treatment patterns, and evidence from routine care. At the same time, these studies do not avoid the need for methodological discipline. Along the way, Jullia and Tom highlight common misconceptions and failure modes, such as assuming real-world data are automatically representative, treating matching as a complete fix for bias, or overlooking how missing data and timing differences can affect the final analysis.
🎧 Listen to the Episode:
Key Takeaways
What Observational Studies Are and Why They Matter
Observational studies are non-interventional studies, which means treatment is not assigned by the protocol but observed as part of routine care. That makes them useful when teams want to understand how therapies are used and how outcomes unfold in settings that look more like real clinical practice. They are especially valuable for questions around broader populations, longer follow-up, treatment patterns, and situations where a randomised study may be difficult or impractical. Their strength comes from offering evidence that complements controlled trials rather than replacing them.
How Risk and Bias Show Up in Practice
The main challenge with observational studies is that treatment groups often differ before analysis even starts. Clinicians make treatment decisions based on factors such as disease severity, prior response, comorbidities, and access, and those differences can distort crude comparisons. Data source limitations add another layer of risk. Timing may not align cleanly across systems, outcomes may be recorded inconsistently, and missing data can weaken interpretation. These issues usually appear in ordinary delivery details, from incomplete lab capture to uneven follow-up windows, rather than in one obvious methodological failure.
Design, Analysis, and Best Practice
A strong observational study begins with a precise question and a realistic check of whether the available data can answer it well. Teams need to understand baseline imbalances, define exposures and outcomes carefully, and choose analysis methods that fit the structure of the data. Approaches such as matching, weighting, and regression adjustment can improve comparability, but they do not remove all bias, especially when important confounders are unmeasured. Good practice includes careful protocol planning, transparent variable definitions, and sensitivity analyses that show how conclusions change under different reasonable assumptions.
Full Transcript
Jullia
Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.
Tom
I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.
Jullia
Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.
Tom
Now observational studies come up all the time, especially when people are talking about real-world evidence. But the term still gets used quite loosely. So when you say observational study, what are you actually referring to?
Jullia
So an observational study is a non-interventional study where researchers observe what happens in routine care without assigning treatment through a protocol. Patients receive whatever care their clinician would normally choose, and the study captures exposures, outcomes, and other relevant variables as they arise.
What matters straight away is that the investigator isn’t controlling treatment allocation, blinding, or adherence in the way you would in a randomised controlled trial. That changes how you design the study, how you analyse the data, and how confident you can be about the conclusions.
Tom
So you’re saying the distinction isn’t really about whether the data came from a registry or an electronic record. It’s about who’s controlling the treatment decision?
Jullia
Yeah so you can use several data sources, but the defining feature is that the treatment happened as part of usual care. You might be using insurance claims, general practice records, hospital data, pharmacy records, or disease registries.
And those sources all behave differently. A claims dataset might give you broad coverage and treatment patterns, but not much clinical detail. A registry might give you richer disease information, but with tighter inclusion rules and a different set of missing data problems.
Tom
I think a lot of people underestimate that. They hear “real-world” and assume the data are somehow naturally representative and ready to go. Where do you tend to see teams getting caught early?
Jullia
So it’s often at the point where the data look abundant but the study question is still a bit loose. If you haven’t defined the exposure, outcome, and baseline period carefully, you can create problems before any modelling starts.
Now a common scenario is treatment comparison where one group is identified from prescribing records and the outcome comes from hospital events. Sounds straightforward, but then you realise the timing windows don’t line up cleanly, or a dosing change is visible in one system and not another. That’s when simple assumptions start creating bias.
Tom
And before we get into the analysis side, it’s probably worth grounding the main study designs. Because people often say “cohort study” as if that covers the whole field.
Jullia
Yes, and it doesn’t. Cohort studies are one type of observational study, but not the only one. In a cohort study, you follow groups over time and compare outcomes between people with different exposures or treatments.
Now case-control studies work the other way round. You start with the outcome and look back at prior exposures. Cross-sectional studies give you a snapshot at one point in time. Then you’ve got case series and registries, which can be especially useful for describing disease course, treatment patterns, or uncommon settings where hypothesis generation is the immediate goal.
Tom
So why do teams keep coming back to observational studies, given all the caveats?
Jullia
Because they answer questions that controlled trials often can’t answer on their own. Observational studies can show how treatments perform in broader and more heterogeneous populations, over longer periods, and in day-to-day clinical settings. This would typically be where adherence, comorbidities, and treatment switching are part of the picture.
They can also be faster and less resource-intensive, especially when the data already exist. And they’re valuable when randomised trials are difficult to run for ethical or practical reasons. Rare diseases are a good example. If recruitment is very limited, a registry or another structured real-world dataset may be the only realistic way to study progression or treatment use at all.
Tom
That makes sense. But the trade-off is bias, and that’s where people can get overconfident. Now what tends to go wrong there?
Jullia
So the biggest issue is that treatment groups usually differ before the analysis even begins. Clinicians prescribe based on severity, prior response, comorbidities, access, all sorts of things. So if one treatment is channelled towards sicker patients, a crude comparison can make it look worse even when the treatment itself isn’t the reason.
Then you have information bias and measurement problems. One site may record symptom changes carefully, another may do it loosely. Lab values may come from different systems. Outcomes can be misclassified. Missing data are everywhere. Even something as ordinary as query turnaround on an adverse event entry can affect what is available for analysis and when. That’s why observational work needs very deliberate planning.
Tom
And is it true that sometimes the result changes once you split the data properly? People see one headline number, then a stratified analysis tells a different story.
Jullia
Yes, that can happen, and it’s a reminder that aggregated results can hide important structure. If a third variable is driving both treatment choice and outcome, the overall estimate may be misleading unless you understand that relationship properly.
This is where baseline review matters more than people think. Before fitting any formal model, you need to look carefully at how the groups differ. Age, disease severity, prior treatment, comorbidities, care setting, follow-up time. You’re trying to understand the data-generating process, not just decorate a methods section.
Tom
So let’s talk about what the analysis can actually do. Not fix everything, obviously, but improve the credibility of the comparison.
Jullia
Yeah that’s the right way to frame it. Analytical methods can reduce bias from observed differences and help you test how robust the conclusions are. Matching and weighting are common approaches when you want to make treatment groups more comparable based on measured covariates.
Now propensity scores often come in here. They summarise the probability of receiving a treatment based on observed baseline characteristics, and you can use that for matching, stratification, or weighting. After that, regression adjustment may still be needed for remaining imbalance. And then sensitivity analyses are essential, because the question isn’t only “what estimate did we get?” It’s also “how much does that estimate move when we make different reasonable assumptions?”
Tom
Could you give a concrete example of where that matters, day to day?
Jullia
So imagine you’re comparing two treatments using routine hospital and pharmacy data. One group has more severe patients at baseline, and refill timing is a bit patchy in one region. If you run an unadjusted outcome analysis, you may be mixing treatment effect with baseline severity and exposure mismeasurement.
So you’d start by characterising those baseline differences, then use an approach like matching or weighting where appropriate, then model the outcome with relevant covariates still included. If exposure timing is uncertain, you might run sensitivity analyses with different exposure definitions. That sequence won’t remove unmeasured confounding, but it gives a far more honest basis for interpretation.
Tom
And there are limits to matching as well. Sometimes people talk as if once you’ve matched, the problem is solved.
Jullia
Yes, and that’s a common misconception. Matching only works when there’s enough overlap between groups. If the treated and untreated populations are very different, you can lose a lot of patients trying to force comparability.
That has consequences. The analysable sample gets smaller, and the population you end up studying may no longer reflect the routine practice population you cared about in the first place. You can improve internal comparability, but narrow the real-world relevance at the same time. Teams need to recognise that trade-off rather than treating matching as an automatic quality upgrade.
Tom
There’s also a wider expectation now that real-world evidence should be methodologically transparent if it’s going to carry weight. Regulators are clearly paying attention to design, data quality, and traceability.
Jullia
They are, and that’s pushed the field in a useful direction. Current guidance and regulatory thinking place a lot of emphasis on whether the data are fit for purpose, whether the study design is credible, and whether the analysis is transparent and reproducible.
That means observational studies can’t rely on broad claims about being more reflective of practice. Teams need a clear protocol, well-defined variables, justified analytical choices, and enough documentation that someone else can follow the logic. The methods have to stand up scientifically, whether the study supports internal decision-making, safety evaluation, or a broader evidence package.
Tom
So if someone’s scoping an observational study now, what are the main things they should keep in view from the start?
Jullia
I’d keep it very grounded. First, make the study question precise and test whether the available data can answer it cleanly. Second, spend real time understanding baseline differences and data limitations before choosing the modelling strategy. Third, plan for uncertainty with sensitivity analyses instead of treating one adjusted estimate as the whole story.
If those three pieces are in place, the study is much more likely to produce evidence that people can actually use. And the wider lesson is fairly simple. Observational studies are valuable because they show treatment use and outcomes in routine care, they depend heavily on data quality and design discipline, and they need careful analysis because bias is built into the setting rather than added at the end.
Tom
That’s a good place to leave it. Observational studies can answer important questions, but only when the design, data, and analysis are pulling in the same direction.
Jullia
With that, we’ve come to the end of today’s episode on observational studies. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.
Tom
Thanks for tuning in, and we’ll see you in the next episode.
About QCast
QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.
Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.
